Drugs / IVX-241
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05664334 | Sep 2022 → Jan 2024 | — | Icosavax, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVX-241 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05664334 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM) once on Day 0.” NCT05664334 ↗ |